Moss, 12 March 2026
Gentian Diagnostics ASA (the "Company") has completed the offer of new shares to employees in the Company and its subsidiaries under the Gentian Employee Share Purchase Program (the "Employee Share Purchase Program"). The application period expired on 11 March 2026 at 16:00 CET. Under the program, each participating employee could subscribe for shares for a maximum total subscription amount of NOK 100,000.
The offer price for the shares in the Employee Share Purchase Program has been set to NOK 32.58 per share (the "Offer Price"). The Offer Price is based on the volume-weighted average share price for the Company's shares on the Oslo Stock Exchange during the ten trading days from 12 February 2026 to and including 25 February 2026, less a discount of 20%. Shares acquired under the Employee Share Purchase Program will be subject to a lock-up period of one year.
Based on the applications received, the board of directors has allocated a total of 36,274 new shares to participants in the Employee Share Purchase Program (the "Program Shares").
The board of directors has, based on the authorisation granted by the annual general meeting held on 6 May 2025, resolved to increase the Company's share capital by NOK 3627,4 through the issuance of 36,274 new shares, each with a nominal value of NOK 0,10, at a subscription price equal to the Offer Price.
Following registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret), the Company's share capital will be NOK 1,545,862.4, divided into 15,458,624 shares, each with a nominal value of NOK 0,10.
For further information, please contact:
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.